Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → Buy |
| 08/16/2023 | 4230.57% | Chardan Capital | $14 → $12 | Maintains | Buy |
| 06/26/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | Buy → Buy |
| 05/25/2023 | 2317.9% | EF Hutton | → $6.7 | Assumes | → Buy |
| 05/11/2023 | 4952.33% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 04/19/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 04/19/2023 | 6034.97% | Chardan Capital | $22 → $17 | Maintains | Buy |
| 02/15/2023 | 2317.9% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 2317.9% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 7839.37% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 621.76% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 621.76% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 802.2% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 621.76% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 1704.4% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 2787.04% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 2426.16% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/23/2023 | 2317.9% | EF Hutton | → 6.7 美元 | 假設 | → 購買 |
| 08/16/2023 | 4230.57% | 查丹資本 | 14 美元 → 12 美元 | 維護 | 購買 |
| 06/26/2023 | 2317.9% | EF Hutton | → 6.7 美元 | 重申 | 購買 → 購買 |
| 05/25/2023 | 2317.9% | EF Hutton | → 6.7 美元 | 假設 | → 購買 |
| 05/11/2023 | 4952.33% | 查丹資本 | 17 美元 → 14 美元 | 維護 | 購買 |
| 04/19/2023 | 2317.9% | EF Hutton | → 6.7 美元 | 重申 | → 購買 |
| 04/19/2023 | 6034.97% | 查丹資本 | 22 美元 → 17 美元 | 維護 | 購買 |
| 02/15/2023 | 2317.9% | EF Hutton | → 6.7 美元 | 重申 | → 購買 |
| 2022 年 12 月 19 日 | 2317.9% | EF Hutton | → 6.7 美元 | 啓動覆蓋開啓 | → 購買 |
| 2022 年 9 月 22 日 | 7839.37% | 查丹資本 | $2 → 22 美元 | 維護 | 購買 |
| 08/16/2022 | 621.76% | 查丹資本 | 2.5 美元 → 2 美元 | 維護 | 購買 |
| 02/09/2022 | 621.76% | BTIG | 5 美元 → 2 美元 | 維護 | 購買 |
| 2021 年 12 月 20 日 | 802.2% | 查丹資本 | 8 美元 → 2.5 美元 | 維護 | 購買 |
| 2021 年 12 月 16 日 | 621.76% | HC Wainwright & Co. | → 2 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 9 月 15 日 | 1704.4% | BTIG | → 5 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 4 月 9 日 | 2787.04% | 查丹資本 | 7 美元 → 8 美元 | 維護 | 購買 |
| 2020 年 5 月 6 日 | 2426.16% | 查丹資本 | → 7 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Sonnet BioTherapeutics (SONN)?
Sonnet Biotherapeutics（SONN）的目標價格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by EF Hutton on August 23, 2023. The analyst firm set a price target for $6.70 expecting SONN to rise to within 12 months (a possible 2317.90% upside). 10 analyst firms have reported ratings in the last year.
英孚赫頓於2023年8月23日公佈了Sonnet Biotherapeutics（納斯達克股票代碼：SONN）的最新目標股價。該分析公司將目標股價定爲6.70美元，預計SONN將在12個月內上漲至23.17.90％（可能上漲2317.90％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
分析師對Sonnet Biotherapeutics（SONN）的最新評級是多少？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by EF Hutton, and Sonnet BioTherapeutics their buy rating.
英孚赫頓爲Sonnet Biotherapeutics（納斯達克股票代碼：SONN）提供了最新的分析師評級，Sonnet BioTherapeutics提供了買入評級。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Sonnet BioTherapeutics（SONN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括閱讀公開財務報表、與Sonnet BioTherapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Sonnet Biotherapeutics的最後一次評級是在2023年8月23日提交的，因此你應該預計下一個評級將在2024年8月23日左右公佈。
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析師對 Sonnet BioTherapeutics (SONN) 的評級正確嗎？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.28, which is within the analyst's predicted range.
雖然評級是主觀的，並且會發生變化，但最新的Sonnet BioTherapeutics（SONN）評級爲0.00美元至6.70美元。Sonnet Biotherapeutics（SONN）目前的交易價格爲0.28美元，在分析師的預測區間內。